e-Therapeutics successfully tested; now looking for industry partners

0
25
  • e-Therapeutics eyes industry partnerships following the successful testing of its technology
  • e-therapeutics explain launch of trading on OTCQX Best Markets and progress on its RNAi Platform
scientist in a lab

Quick facts: e-Therapeutics PLC

Follow

View company profile

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity.

The company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

26 Oct 2021

e-Therapeutics PLC said it expects to offer “early-stage business development opportunities to potential partners in the coming months” following successful lab testing of its lead technology.

The company uses small interfering RNA, sometimes known as silencing RNA, and couples, or ‘conjugates’ it with a drug technology that ensures it gets to the right cells in the liver.

These so-called GaINAc-siRNA ‘constructs’ were assessed as part of a characterisation study.

The research demonstrated e-Therapeutics’ approach was equivalent in performance to leading competitor programmes showing “deep and durable target gene knock-down”.

Read more

11 Oct 2021

e-Therapeutics plc has unveiled new patent filings to protect its proprietary RNAi platform technology for liver gene silencing.

The computational drug discovery specialist recently filed five new patent applications relating to its GalNAc-conjugated siRNA (short interfering RNA) construct designs, including for stabilising chemical modifications enabling specific hepatocyte (liver cell) targeting.

Read more

24 Sep 2021

Blue Sky Uranium Corp received a positive report from Globe Small Cap Research LLC, citing the growth in the global nuclear industry and business relations with the Argentinian government as catalysts to continued success for the uranium developer. Another tailwind for the company is the rising price of uranium. Spot U3O8 values have skyrocketed to a 12-year high this year – US$50.25 per pound) – and are anticipated to continue this trajectory as more countries build out their nuclear fleets and small modular reactors become more prevalent. “[Blue Sky] operates in a hot space with stellar growth opportunities and deserves consideration by risk adverse micro and small cap-oriented investors,” the report stated.

Todos Medical Ltd, a medical diagnostics company, posted second-quarter results that saw its revenue rocket more than 50 times year-over-year fueled by its coronavirus (COVID-19) distribution business. For the period ended June 30, 2021, Todos reported revenue of $1.7 million, compared to $32,000 in the second quarter of 2020. Todos, which has a strong presence in New York and Tel Aviv, chalked up the revenue increase to sales from the company’s COVID-19 product distribution business. Investors responded well, sending Todos shares nearly 6.4% higher to $0.04 on the OTC Markets. Todos narrowed its operating loss to $1,662,0000 in 2Q 2021, compared to an operating loss of $1,719,000 in the same period a year earlier. CEO Gerald Commissiong said Todos is focused on ‘ramping testing volume at Provista, growing revenue at our COVID distribution business,’ and developing antivirals, supplements and diagnostic solutions.

Read more

26 Oct 2021

e-therapeutics PLC Chief executive Ali Mortazavi joins Proactive London after the recent launch of trading on the OTCQX Best Market under the ticker symbol ETXPF. He says this platform would help broaden the shareholder base.

He says their computational biology and RNAi therapeutics platforms are particularly suited to a global audience and they look forward to sharing the Company’s equity story with an international audience.

He also explains the progress on its RNAi Platform with results from characterisation benchmarking studies now successfully completed. The research demonstrated e-Therapeutics’ approach was equivalent in performance to leading competitor programmes showing ‘deep and durable target gene knock-down’.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

e-therapeutics presents results demonstrating ‘significant progress’ on its…

e-therapeutics PLC’s (LON:ETX) CEO Ali Mortazavi talks to Proactive London about their six months results and successful lab testing of its lead technology.

He details further progress on its RNAi Platform with results from characterisation benchmarking studies now successfully…

4 hours, 48 minutes ago

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here